Country: Canada
Language: English
Source: Health Canada
PIMOZIDE
AA PHARMA INC
N05AG02
PIMOZIDE
4MG
TABLET
PIMOZIDE 4MG
ORAL
100
Prescription
MISCELLANEOUS ANTIPSYCHOTICS
Active ingredient group (AIG) number: 0109963003; AHFS:
APPROVED
2002-02-19
PRODUCT MONOGRAPH PR PIMOZIDE PIMOZIDE TABLETS USP 2 MG AND 4 MG ANTIPSYCHOTIC AA PHARMA INC. DATE OF PREPARATION: 1165 CREDITSTONE ROAD, UNIT #1 MARCH 11, 2014 VAUGHAN, ONTARIO L4K 4N7 CONTROL NO.: 172057 2 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ........................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................... 4 ADVERSE REACTIONS ......................................................................................................... 9 DRUG INTERACTIONS ....................................................................................................... 11 DOSAGE AND ADMINISTRATION ................................................................................... 13 OVERDOSAGE ...................................................................................................................... 14 ACTIONS AND CLINICAL PHARMACOLOGY ............................................................... 15 STABILITY AND STORAGE RECOMMENDATIONS ..................................................... 15 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................. 15 PART II: SCIENTIFIC INFORMATION ............................................................................. 17 PHARMACEUTICAL INFORMATION ............................................................................... 17 CLINICAL TRIALS ............................................................................................................... 18 DETAILED PHARMACOLOGY .......................................................................................... 18 TOXI Read the complete document